Latigo Biotherapeutics Q2 net loss $25.8 million; cash $55.0 million after August IPO
Latigo Biotherapeutics reported a second-quarter 2026 net loss of $25.8 million, unchanged from the same quarter of 2025, as lower research and development expenses offset higher general and administrative costs. The company said it completed an upsized initial public offering in August 2026 with gross proceeds of $397.4 million, and that cash and the IPO proceeds are projected to fund operations into 2029.
Key points
- Net loss was $25.8 million for the three months ended June 30, 2026, and for the same period in 2025.
- Research and development expenses fell to $21.2 million from $22.9 million; general and administrative expenses rose to $4.6 million from $2.8 million.
- IPO completed in August 2026 with gross proceeds of $397.4 million, before underwriting discounts, commissions and other offering expenses.
- Cash and cash equivalents were $55.0 million as of June 30, 2026, before the IPO proceeds.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.